Embecta Corp.

Background

Company Name	Embecta Corp.
Stock Symbol	EMBC
Class Period	November 25, 2025 to May 04, 2026
Lead Plaintiff Motion Deadline	August 17, 2026

Submit Your Information

If you suffered a loss on your Embecta Corp. investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below. Please note that submission of this form does not by itself form an attorney-client relationship nor does filling out this form mean you have joined any lawsuit.

First Name*

Middle Initial

Last Name*

Email*

Phone*

If representing a Corporation, Trust, Partnership or other entity, Name of Entity

If representing an Entity, Position at Entity

Mailing Address

City

State/Province

ZIP/Postal Code

Country

Are you a current or former employee of the company?

Did you purchase any shares before November 25, 2025?

Shares Purchased

Number of Shares	Buy Date	Price Per Share	Add
Purchased quantity	Purchased month Purchased day Purchased year

Shares Sold

Number of Shares	Sell Date	Price Per Share	Add
	Sold month Sold day Sold year

Additional Comments

Background

On May 5, 2026, Embecta released its second quarter fiscal 2026 financial results, revealing that revenue had declined over 14%, largely due to weakness in its pen needle sales. Additionally, the Company lowered its guidance for the remainder of fiscal 2026.

On this news, Embecta’s stock price fell $5.35, or 57.8%, to close at $3.90 per share on May 5, 2026, thereby injuring investors.

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) the Company’s guidance was misleading and unattainable; (2) segment weakness, especially in the United States pen needle market, was likely to disrupt the Company’s original revenue guidance and second quarter 2026 results; and (3) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Submit Your Information